Reports

435 Results (Page 2 of 37)

Clinical Trials Markets Research Reports

Clinical Trials

Turkey Oncology Clinical Trials Market Analysis

Turkey's oncology clinical trials market is projected to grow from $101.2 Mn in 2022 to $161.3 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by the country's expanding healthcare infrastructure and increased emphasis on R&D. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & Deva Holding.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Tanzania Oncology Clinical Trials Market Analysis

Tanzania's oncology clinical trials market is projected to grow from $5.06 Mn in 2022 to $8.31 Mn by 2030, registering a CAGR of 6.4% during the forecast period of 2022-30. The market will be driven by the country's high cancer burden and its rising expenditure on research and development. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & Novartis International AG.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Vietnam Oncology Clinical Trials Market Analysis

Vietnam's oncology clinical trials market is projected to grow from $63.3 Mn in 2022 to $98.8 Mn by 2030, registering a CAGR of 5.73% during the forecast period of 2022-30. The market will be driven by the big and diversified patient population available for clinical trials and a well-established clinical trial regulatory structure. The market is segmented by phase, by study design & by indication. Some of the major players include AstraZeneca PLC, Novartis AG & Hau Giang Pharmaceutical Joint Stock Company.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Thailand Oncology Clinical Trials Market Analysis

Thailand’s oncology clinical trials market is projected to grow from $15.2 Mn in 2022 to $23.9 Mn by 2030, registering a CAGR of 5.84% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer along with the country's strategic position and inexpensive clinical trial costs. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., FHoffmann-La Roche Ltd & Siam Bioscience Co., Ltd.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Singapore Oncology Clinical Trials Market Analysis

Singapore's oncology clinical trials market is projected to grow from $15.2 Mn in 2022 to $24.4 Mn by 2030, registering a CAGR of 6.1% during the forecast period of 2022-30. The market will be driven by the rising number of cancer cases and a favorable regulatory climate for clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & Aslan Pharmaceuticals.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Philippines Oncology Clinical Trials Market Analysis

The Philippines oncology clinical trials market is projected to grow from $27.8 Mn in 2022 to $44.4 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by the growing cancer burden, favorable regulatory environment, and cheaper costs. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & AstraZeneca plc.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Malaysia Oncology Clinical Trials Market Analysis

Malaysia's oncology clinical trials market is projected to grow from $20.3 Mn in 2022 to $31.7 Mn by 2030, registering a CAGR of 5.7% during the forecast period of 2022-30. The market will be driven by the rise of oncology clinical trials in Malaysia, a well-established clinical research infrastructure, and government funding. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & Biocon Malaysia.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Japan Oncology Clinical Trials Market Analysis

Japan's oncology clinical trials market is projected to grow from $0.79 Bn in 2022 to $1.25 Bn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by a well-established healthcare system, advanced infrastructure, and a high prevalence of cancer. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, Chugai Pharmaceutical Co., Ltd. & Ono Pharmaceutical Co., Ltd.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Egypt Oncology Clinical Trials Market Analysis

Egypt's oncology clinical trials market is projected to grow from $35.4 Mn in 2022 to $60.9 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by Egypt's rising cancer incidence and the government's favorable regulatory framework for clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International, EIPICO & EVA Pharma

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Brazil Oncology Clinical Trials Market Analysis

Brazil's oncology clinical trials market is projected to grow from $316.3 Mn in 2022 to $523.4 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022-30. The market will be driven by the increased investment in healthcare and research and the rise in oncology clinical trials owing to rising cancer cases in Brazil. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & Eurofarma Laboratórios S.A.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Australia Oncology Clinical Trials Market Analysis

Australia's oncology clinical trials market is projected to grow from $151.8 Mn in 2022 to $260.8 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by the rising investment in clinical research, increased patient education and engagement, and the development of new and innovative clinical trial designs. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, AstraZeneca plc & Kazia Therapeutics Limited.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

UK Oncology Clinical Trials Market Analysis

The UK oncology clinical trials market is projected to grow from $328.9 Mn in 2022 to $433.1 Mn by 2030, registering a CAGR of 3.50% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer in the UK and efforts to promote research, collaboration, and innovation. The market is segmented by phase, study design, and indication. Some of the major players include Novartis AG, AstraZeneca & Astex Pharmaceuticals.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

UAE Oncology Clinical Trials Market Analysis

The UAE oncology clinical trials market is projected to grow from $63.3 Mn in 2022 to $104.7 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022-30. The market will be driven by the rising rate of cancer in the UAE and investments in developing healthcare infrastructure and research capabilities to support the field. The market is segmented by phase, study design, and indication. Some of the major players include Pfizer Inc, FHoffmann-La Roche Ltd & Julphar

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Romania Oncology Clinical Trials Market Analysis

Romania's oncology clinical trials market is projected to grow from $36.7 Mn in 2022 to $57.4 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022-30. The market will be driven by the country’s rising incidence of cancers and supportive regulatory environment. The market is segmented by phase, by study design & by indication. Some of the major players include Roche Holding AG, Pfizer Inc. & Biofarm SA.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Netherlands Oncology Clinical Trials Market Analysis

Netherlands oncology clinical trials Market is projected to grow from $32.9 Mn in 2022 to $52.4 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by the country's strong healthcare system, experienced clinical researchers, and a supportive government. The market is segmented by phase, by study design & by indication. Some of the major players include Roche Holding AG, Pfizer Inc & Kiadis Pharma.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Italy Oncology Clinical Trials Market Analysis

Italy's oncology clinical trials market is projected to grow from $303.6 Mn in 2022 to $448.6 Mn by 2030, registering a CAGR of 5% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer in Italy & well-established research infrastructure and regulatory environment. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & MolMed S.p.A.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

India Oncology Clinical Trials Market Analysis

India's oncology clinical trials market is projected to grow from $230.1 Mn in 2022 to $441.8 Mn by 2030, registering a CAGR of 8.5% during the forecast period of 2022-30. The market will be driven by the rising prevalence of Oncological disorders, the availability of a large patient pool with various genetic profiles, and low-cost clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd. & Cipla Ltd.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Germany Oncology Clinical Trials Market Analysis

Germany's oncology clinical trials market is projected to grow from $463 Mn in 2022 to $619.2 Mn by 2030, registering a CAGR of 3.7% during the forecast period of 2022-30. The market will be driven by the strong healthcare infrastructure, focus on personalized medicine, and experienced workforce. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Roche Holding AG, Bayer AG & BioNTech SE.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

France Oncology Clinical Trials Market Analysis

The France oncology clinical trials market is projected to grow from $347.9 Mn in 2022 to $494.7 Mn by 2030, registering a CAGR of 4.5% during the forecast period of 2022-30. The market will be driven by the rising prevalence of cancer cases, the modern healthcare system in the nation, and a supportive regulatory framework. The market is segmented by phase, by study design & by indication. Some of the major players include Roche Holding AG, Transgene & Ipsen.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

China Oncology Clinical Trials Market Analysis

China's oncology clinical trials market is projected to grow from $1.02 Bn in 2022 to $1.75 Bn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer in the country and efforts to promote research, collaboration, and innovation. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Roche Holding AG, Jiangsu Hengrui Pharmaceutical & Sino Biopharmaceutical.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Belgium Oncology Clinical Trials Market Analysis

The Belgium oncology clinical trials market is projected to grow from $27.8 Mn in 2022 to $42.7 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022-30. The market will be driven by increasing demand for innovative cancer therapies and a growing focus on personalized medicine. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & Galapagos NV.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Tanzania Neurology Clinical Trials Market Analysis

The Tanzania Neurology Clinical Trials market is projected to grow from $2.09 Mn in 2022 to $3.44 Mn by 2030, registering a CAGR of 6.4% during the forecast period of 2022 - 2030. The market will be driven by investment in infrastructure, resources, and training for healthcare professionals, as well as collaboration between local and international stakeholders. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Sanofi S.A., AstraZeneca & GlaxoSmithKline.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

South Africa Neurology Clinical Trials Market Analysis

The South Africa Neurology Clinical Trials market is projected to grow from $34 Mn in 2022 to $57.2 Mn by 2030, registering a CAGR of 6.73% during the forecast period of 2022 - 2030. The market will be driven by the availability of a diverse population, a large number of well-trained healthcare professionals and modern medical healthcare facilities. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Eli Lilly and Company & Biovac.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Romania Neurology Clinical Trials Market Analysis

The Romania Neurology Clinical Trials market is projected to grow from $15.2 Mn in 2022 to $23.7 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022 - 2030. The market will be driven by collaborations with international research institutions and improved funding for clinical research. The market is segmented by phase, by study design & by indication. Some of the major players include Biogen Inc., Pfizer Inc. & Novartis AG.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

Clinical Trials

Poland Neurology Clinical Trials Market Analysis

The Poland Neurology Clinical Trials market is projected to grow from $30.3 Mn in 2022 to $48.2 Mn by 2030, registering a CAGR of 5.95% during the forecast period of 2022 - 2030. The market will be driven by a skilled workforce, a supportive regulatory framework, and a relatively low cost of conducting research. The market is segmented by phase, by study design & by indication. Some of the major players include Biogen Inc., Pfizer Inc. & Novartis AG.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Mar, 2023
$ 3999

subscribe to our newsletter
up